{{!--
  Investigator's Brochure - Generic Product
  Section 4: Nonclinical Studies
  
  Template for ICH E6 (R2) compliant IB Section 4
  
  Data Sources:
  - nonclinical_summary (pharmacology, toxicology)
  - label (nonclinical sections)
  - literature (nonclinical studies)
  
  Variables:
  - compound_name: string
  - generic_name: string
  - rld_brand_name: string
  - product_type: string
  - nonclinical_summary: NonclinicalSummary
  - label: Label
  - literature: Literature[]
--}}

# 4. NONCLINICAL STUDIES

{{#if eq product_type "generic"}}
## 4.0 Note on Generic Products

As a generic product bioequivalent to the Reference Listed Drug (RLD) {{rld_brand_name}}, {{compound_name}} relies on the nonclinical safety database established for the RLD. Generic products are not required to repeat nonclinical studies when bioequivalence to an approved RLD has been demonstrated.

The nonclinical information presented in this section is derived from the RLD's approved labeling and published scientific literature. This data supports the safety profile of {{compound_name}} based on its pharmaceutical equivalence and bioequivalence to {{rld_brand_name}}.

---
{{/if}}

## 4.1 Pharmacology Studies

### 4.1.1 Primary Pharmacodynamics

{{#if nonclinical_summary.pharmacology.primary}}
**Mechanism of Action:**
{{nonclinical_summary.pharmacology.primary.mechanism}}

**Target Receptors/Enzymes:**
{{#each nonclinical_summary.pharmacology.primary.targets}}
- {{this.target}}: {{this.effect}} ({{this.potency}})
{{/each}}

**In Vitro Studies:**
{{#each nonclinical_summary.pharmacology.primary.in_vitro}}
- **{{this.study}}:** {{this.result}}
{{/each}}

**In Vivo Studies:**
{{#each nonclinical_summary.pharmacology.primary.in_vivo}}
- **{{this.model}}:** {{this.result}}
{{/each}}
{{else}}
**Mechanism of Action:** [Describe primary mechanism of action based on RLD data]

**Target Receptors/Enzymes:** [List primary targets]

**In Vitro Studies:** [Summarize key in vitro pharmacology studies]

**In Vivo Studies:** [Summarize key in vivo pharmacology studies in animal models]
{{/if}}

### 4.1.2 Secondary Pharmacodynamics

{{#if nonclinical_summary.pharmacology.secondary}}
**Off-Target Effects:**
{{#each nonclinical_summary.pharmacology.secondary.off_targets}}
- {{this.target}}: {{this.effect}}
{{/each}}

**Secondary Activities:**
{{#each nonclinical_summary.pharmacology.secondary.activities}}
- {{this}}
{{/each}}
{{else}}
**Off-Target Effects:** [Describe any known off-target pharmacological effects]

**Secondary Activities:** [Describe secondary pharmacological activities]
{{/if}}

### 4.1.3 Safety Pharmacology

{{#if nonclinical_summary.safety_pharmacology}}
**Cardiovascular System:**
{{#if nonclinical_summary.safety_pharmacology.cardiovascular}}
{{nonclinical_summary.safety_pharmacology.cardiovascular}}
{{else}}
[Describe effects on cardiovascular system: heart rate, blood pressure, ECG, etc.]
{{/if}}

**Central Nervous System:**
{{#if nonclinical_summary.safety_pharmacology.cns}}
{{nonclinical_summary.safety_pharmacology.cns}}
{{else}}
[Describe effects on CNS: behavior, motor activity, coordination, etc.]
{{/if}}

**Respiratory System:**
{{#if nonclinical_summary.safety_pharmacology.respiratory}}
{{nonclinical_summary.safety_pharmacology.respiratory}}
{{else}}
[Describe effects on respiratory system: rate, tidal volume, etc.]
{{/if}}

**Renal System:**
{{#if nonclinical_summary.safety_pharmacology.renal}}
{{nonclinical_summary.safety_pharmacology.renal}}
{{else}}
[Describe effects on renal function if evaluated]
{{/if}}

**Gastrointestinal System:**
{{#if nonclinical_summary.safety_pharmacology.gastrointestinal}}
{{nonclinical_summary.safety_pharmacology.gastrointestinal}}
{{else}}
[Describe effects on GI system if evaluated]
{{/if}}
{{else}}
**Safety Pharmacology Studies:**

[Summarize safety pharmacology studies conducted on vital organ systems]

- **Cardiovascular:** [Effects on heart rate, blood pressure, ECG]
- **Central Nervous System:** [Effects on behavior, motor function]
- **Respiratory:** [Effects on respiratory function]
{{/if}}

---

## 4.2 Pharmacokinetics in Animals

### 4.2.1 Absorption

{{#if nonclinical_summary.pharmacokinetics.absorption}}
**Bioavailability:**
{{#each nonclinical_summary.pharmacokinetics.absorption.bioavailability}}
- **{{this.species}}:** {{this.value}}% ({{this.route}})
{{/each}}

**Absorption Rate:**
{{nonclinical_summary.pharmacokinetics.absorption.rate_description}}

**Food Effects:**
{{#if nonclinical_summary.pharmacokinetics.absorption.food_effect}}
{{nonclinical_summary.pharmacokinetics.absorption.food_effect}}
{{else}}
[Describe food effects if studied]
{{/if}}
{{else}}
**Bioavailability:** [Describe bioavailability in animal species]

**Absorption Rate:** [Describe absorption characteristics]

**Food Effects:** [Describe food effects if studied]
{{/if}}

### 4.2.2 Distribution

{{#if nonclinical_summary.pharmacokinetics.distribution}}
**Volume of Distribution:**
{{#each nonclinical_summary.pharmacokinetics.distribution.volume}}
- **{{this.species}}:** {{this.value}} L/kg
{{/each}}

**Protein Binding:**
{{#each nonclinical_summary.pharmacokinetics.distribution.protein_binding}}
- **{{this.species}}:** {{this.value}}%
{{/each}}

**Tissue Distribution:**
{{nonclinical_summary.pharmacokinetics.distribution.tissue_description}}

**Blood-Brain Barrier Penetration:**
{{#if nonclinical_summary.pharmacokinetics.distribution.bbb_penetration}}
{{nonclinical_summary.pharmacokinetics.distribution.bbb_penetration}}
{{else}}
[Describe BBB penetration if studied]
{{/if}}
{{else}}
**Volume of Distribution:** [Describe Vd in animal species]

**Protein Binding:** [Describe plasma protein binding]

**Tissue Distribution:** [Describe tissue distribution patterns]

**Blood-Brain Barrier:** [Describe BBB penetration if studied]
{{/if}}

### 4.2.3 Metabolism

{{#if nonclinical_summary.pharmacokinetics.metabolism}}
**Metabolic Pathways:**
{{#each nonclinical_summary.pharmacokinetics.metabolism.pathways}}
- {{this.pathway}}: {{this.description}}
{{/each}}

**Enzymes Involved:**
{{#each nonclinical_summary.pharmacokinetics.metabolism.enzymes}}
- {{this}}
{{/each}}

**Metabolites:**
{{#each nonclinical_summary.pharmacokinetics.metabolism.metabolites}}
- **{{this.name}}:** {{this.activity}} ({{this.percentage}}% of dose)
{{/each}}

**Species Differences:**
{{#if nonclinical_summary.pharmacokinetics.metabolism.species_differences}}
{{nonclinical_summary.pharmacokinetics.metabolism.species_differences}}
{{else}}
[Describe species differences in metabolism]
{{/if}}
{{else}}
**Metabolic Pathways:** [Describe primary metabolic pathways]

**Enzymes Involved:** [List metabolizing enzymes]

**Metabolites:** [Describe major metabolites and their activity]

**Species Differences:** [Describe differences between species]
{{/if}}

### 4.2.4 Elimination

{{#if nonclinical_summary.pharmacokinetics.elimination}}
**Half-Life:**
{{#each nonclinical_summary.pharmacokinetics.elimination.half_life}}
- **{{this.species}}:** {{this.value}} hours
{{/each}}

**Clearance:**
{{#each nonclinical_summary.pharmacokinetics.elimination.clearance}}
- **{{this.species}}:** {{this.value}} mL/min/kg
{{/each}}

**Excretion Routes:**
{{#each nonclinical_summary.pharmacokinetics.elimination.routes}}
- **{{this.route}}:** {{this.percentage}}% of dose
{{/each}}

**Excretion Kinetics:**
{{nonclinical_summary.pharmacokinetics.elimination.kinetics_description}}
{{else}}
**Half-Life:** [Describe elimination half-life in animal species]

**Clearance:** [Describe clearance rates]

**Excretion Routes:** [Describe primary excretion routes: renal, hepatic, biliary]

**Excretion Kinetics:** [Describe excretion kinetics]
{{/if}}

---

## 4.3 Toxicology Studies

### 4.3.1 Single-Dose Toxicity

{{#if nonclinical_summary.toxicology.acute}}
**Acute Toxicity Studies:**

{{#each nonclinical_summary.toxicology.acute}}
**{{this.species}} ({{this.route}}):**
- **LD50:** {{this.ld50}}
- **Findings:** {{this.findings}}
- **NOAEL:** {{this.noael}}
{{/each}}

**Target Organs:** {{#if nonclinical_summary.toxicology.acute_target_organs}}{{join nonclinical_summary.toxicology.acute_target_organs ", "}}{{else}}[List target organs]{{/if}}
{{else}}
**Acute Toxicity Studies:**

[Summarize acute toxicity studies in multiple species]

- **Species:** [Species]
- **Route:** [Route of administration]
- **LD50:** [Lethal dose 50%]
- **Findings:** [Key toxicity findings]
{{/if}}

### 4.3.2 Repeat-Dose Toxicity

{{#if nonclinical_summary.toxicology.repeat_dose}}
**Subacute/Subchronic Toxicity:**

{{#each nonclinical_summary.toxicology.repeat_dose}}
**{{this.species}} - {{this.duration}}:**
- **Dose Levels:** {{join this.doses ", "}}
- **NOAEL:** {{this.noael}}
- **Target Organs:** {{join this.target_organs ", "}}
- **Key Findings:** {{this.findings}}
- **Reversibility:** {{this.reversibility}}
{{/each}}

**Chronic Toxicity:**
{{#if nonclinical_summary.toxicology.chronic}}
{{nonclinical_summary.toxicology.chronic}}
{{else}}
[Summarize chronic toxicity studies if conducted]
{{/if}}
{{else}}
**Subacute/Subchronic Toxicity:**

[Summarize repeat-dose toxicity studies]

- **Duration:** [Study duration]
- **Species:** [Species used]
- **Dose Levels:** [Dose levels tested]
- **NOAEL:** [No Observed Adverse Effect Level]
- **Target Organs:** [Organs affected]
- **Findings:** [Key toxicity findings]

**Chronic Toxicity:**

[Summarize chronic toxicity studies if conducted]
{{/if}}

### 4.3.3 Genotoxicity

{{#if nonclinical_summary.toxicology.genotoxicity}}
**In Vitro Studies:**
{{#each nonclinical_summary.toxicology.genotoxicity.in_vitro}}
- **{{this.test}}:** {{this.result}}
{{/each}}

**In Vivo Studies:**
{{#each nonclinical_summary.toxicology.genotoxicity.in_vivo}}
- **{{this.test}}:** {{this.result}}
{{/each}}

**Conclusion:** {{nonclinical_summary.toxicology.genotoxicity.conclusion}}
{{else}}
**In Vitro Studies:**
- **Bacterial Mutation (Ames) Test:** [Result]
- **Chromosomal Aberration Test:** [Result]
- **Mouse Lymphoma Assay:** [Result]

**In Vivo Studies:**
- **Micronucleus Test:** [Result]
- **Other:** [Additional tests if conducted]

**Conclusion:** [Overall genotoxicity assessment]
{{/if}}

### 4.3.4 Carcinogenicity

{{#if nonclinical_summary.toxicology.carcinogenicity}}
**Carcinogenicity Studies:**

{{#each nonclinical_summary.toxicology.carcinogenicity}}
**{{this.species}} - {{this.duration}}:**
- **Dose Levels:** {{join this.doses ", "}}
- **Tumor Findings:** {{this.findings}}
- **Conclusion:** {{this.conclusion}}
{{/each}}

**Overall Assessment:** {{nonclinical_summary.toxicology.carcinogenicity_assessment}}
{{else}}
**Carcinogenicity Studies:**

[Summarize long-term carcinogenicity studies]

- **Species:** [Species used]
- **Duration:** [Study duration]
- **Dose Levels:** [Dose levels tested]
- **Findings:** [Tumor findings]
- **Conclusion:** [Carcinogenic potential assessment]
{{/if}}

### 4.3.5 Reproductive and Developmental Toxicity

{{#if nonclinical_summary.toxicology.reproductive}}
**Fertility Studies:**
{{#if nonclinical_summary.toxicology.reproductive.fertility}}
{{nonclinical_summary.toxicology.reproductive.fertility}}
{{else}}
[Summarize fertility and early embryonic development studies]
{{/if}}

**Embryo-Fetal Development:**
{{#if nonclinical_summary.toxicology.reproductive.embryofetal}}
{{nonclinical_summary.toxicology.reproductive.embryofetal}}
{{else}}
[Summarize embryo-fetal development studies]
{{/if}}

**Pre- and Postnatal Development:**
{{#if nonclinical_summary.toxicology.reproductive.postnatal}}
{{nonclinical_summary.toxicology.reproductive.postnatal}}
{{else}}
[Summarize pre- and postnatal development studies]
{{/if}}

**Pregnancy Category:** {{#if nonclinical_summary.toxicology.reproductive.pregnancy_category}}{{nonclinical_summary.toxicology.reproductive.pregnancy_category}}{{else}}[FDA pregnancy category]{{/if}}
{{else}}
**Fertility Studies:** [Summarize effects on fertility]

**Embryo-Fetal Development:** [Summarize teratogenicity studies]

**Pre- and Postnatal Development:** [Summarize peri/postnatal studies]

**Pregnancy Category:** [FDA pregnancy category]
{{/if}}

### 4.3.6 Local Tolerance

{{#if nonclinical_summary.toxicology.local_tolerance}}
{{nonclinical_summary.toxicology.local_tolerance}}
{{else}}
[Describe local tolerance studies at site of administration]

- **Route:** [Route of administration]
- **Findings:** [Local irritation, sensitization findings]
{{/if}}

---

## 4.4 Special Toxicology Studies

### 4.4.1 Immunotoxicity

{{#if nonclinical_summary.toxicology.immunotoxicity}}
{{nonclinical_summary.toxicology.immunotoxicity}}
{{else}}
[Describe immunotoxicity studies if conducted]
{{/if}}

### 4.4.2 Phototoxicity

{{#if nonclinical_summary.toxicology.phototoxicity}}
{{nonclinical_summary.toxicology.phototoxicity}}
{{else}}
[Describe phototoxicity studies if conducted or if compound has photoreactive potential]
{{/if}}

### 4.4.3 Abuse Liability

{{#if nonclinical_summary.toxicology.abuse_liability}}
{{nonclinical_summary.toxicology.abuse_liability}}
{{else}}
[Describe abuse liability studies if applicable]
{{/if}}

### 4.4.4 Dependence Potential

{{#if nonclinical_summary.toxicology.dependence}}
{{nonclinical_summary.toxicology.dependence}}
{{else}}
[Describe physical and psychological dependence studies if applicable]
{{/if}}

---

## 4.5 Summary of Nonclinical Findings

### 4.5.1 Key Pharmacology Findings

{{#if nonclinical_summary.key_findings.pharmacology}}
{{nonclinical_summary.key_findings.pharmacology}}
{{else}}
[Summarize key pharmacology findings relevant to clinical use]
{{/if}}

### 4.5.2 Key Toxicology Findings

{{#if nonclinical_summary.key_findings.toxicology}}
{{nonclinical_summary.key_findings.toxicology}}
{{else}}
**Target Organs:** [List primary target organs]

**Dose-Limiting Toxicities:** [Describe dose-limiting toxicities]

**Reversibility:** [Describe reversibility of toxicities]

**Safety Margins:** [Describe safety margins relative to clinical doses]
{{/if}}

### 4.5.3 Clinical Relevance

{{#if nonclinical_summary.clinical_relevance}}
{{nonclinical_summary.clinical_relevance}}
{{else}}
[Discuss clinical relevance of nonclinical findings]

**Exposure Multiples:** [Compare animal exposures to human therapeutic exposures]

**Translatability:** [Discuss translatability of animal findings to humans]

**Risk Assessment:** [Overall nonclinical risk assessment]
{{/if}}

---

## 4.6 Supporting Literature

{{#if literature}}
Key nonclinical publications:

{{#each literature}}
{{#if lte @index 4}}
{{add @index 1}}. {{#each this.authors}}{{this}}{{#unless @last}}, {{/unless}}{{/each}}. {{this.title}}. *{{this.journal}}*{{#if this.publication_date}}. {{this.publication_date}}{{/if}}{{#if this.volume}};{{this.volume}}{{/if}}{{#if this.issue}}({{this.issue}}){{/if}}{{#if this.pages}}:{{this.pages}}{{/if}}. PMID: {{this.pmid}}.

{{/if}}
{{/each}}

Additional references are provided in Section 10.
{{else}}
[List key nonclinical publications]

1. [Reference 1]
2. [Reference 2]
3. [Reference 3]

Complete references are provided in Section 10.
{{/if}}

---

## 4.7 Conclusions

{{#if nonclinical_summary.conclusions}}
{{nonclinical_summary.conclusions}}
{{else}}
The nonclinical studies of {{compound_name}} demonstrate:

1. **Pharmacology:** [Summary of pharmacological profile]
2. **Safety:** [Summary of safety profile]
3. **Toxicology:** [Summary of toxicological findings]
4. **Clinical Implications:** [Implications for clinical use]

{{#if eq product_type "generic"}}
As a generic product bioequivalent to {{rld_brand_name}}, {{compound_name}} is expected to have the same nonclinical safety profile as the RLD. The extensive nonclinical database for the RLD supports the safe use of this generic formulation.
{{/if}}

The nonclinical data support the clinical development and use of {{compound_name}} with appropriate monitoring and risk management strategies.
{{/if}}

---

## 4.8 Data Sources

This section was compiled from the following sources:

{{#if nonclinical_summary}}
- **Nonclinical Summary:** {{nonclinical_summary.source}} (Retrieved: {{date nonclinical_summary.retrieved_at "YYYY-MM-DD"}})
{{/if}}
{{#if label}}
- **FDA Label:** {{label.source}} ({{label.effective_date}})
{{/if}}
{{#if literature}}
- **Literature:** {{length literature}} nonclinical articles from PubMed
{{/if}}
{{#if eq product_type "generic"}}
- **RLD Information:** Based on approved labeling for {{rld_brand_name}}
{{/if}}

**Confidence Level:** {{#if nonclinical_summary.confidence}}{{capitalize nonclinical_summary.confidence}}{{else}}High{{/if}}

---

*This section complies with ICH E6 (R2) and ICH M3(R2) guidelines for Investigator's Brochure content.*
